Oversight Committee

Through project selection and review, and periodic assessment of the program, the Oversight Committee ensures the quality of translational projects and the sustainability of the Translational Partnership. The independent Oversight Committee, chaired by the BME Department Chair, includes members from Duke as well as industry and venture capital. 

The roles of the Oversight Committee are:

  1. Assist with team and proposal solicitation and development
  2. Review and select individual translational research projects for funding  
  3. Assess periodic reports for the projects and the program
  4. Evaluate project portfolio
  5. Provide mentoring to teams  
  6. Provide regular feedback to the Program PI, Co-PI and CPD about the program
  7. Provide updates to the senior University administration as needed or requested

The committee members include:

  • Ashutosh Chilkoti, PhD, Chairman and Professor, Biomedical Engineering, Coulter Translational Partnership Grant PI
  • Victoria Christian, Chief Operating Officer, Duke Margolis Center for Health Policy
  • Michael Hill, PhD, MBA, Vice President, Research and Development, Medtronic
  • Robert Morff, PhD, Venture Partner, Hatteras Ventures
  • Barry Myers, MD, Ph.D., MBA Professor of Biomedical Engineering,  Coulter Program Director, Director of Emerging Programs, Duke Translational Research Institute (DTRI), ex officio
  • James Rosen, MBA, Deputy Director of Program Related Investments, Bill and Melinda Gates Foundation
  • Kevin Schulman, MD, Professor of Medicine, Duke University School of Medicine, Professor of Business Administration, Fuqua School of Business
  • Mark Stacy, MD, Vice Dean for Clinical Research and Professor of Neurology, Duke University School of Medicine
  • John Sundy, MD, PhD, Vice President, Inflammation and Respiratory Therapeutics, Gilead Sciences, Inc.